Anika Therapeutics, Inc. (ANIK) — 10-Q Filings
All 10-Q filings from Anika Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Anika Narrows Losses Amid Strategic Divestitures, Revenue Dip
— Nov 5, 2025 Risk: medium
Anika Therapeutics, Inc. (ANIK) reported a net loss of $2.3 million for the three months ended September 30, 2025, a significant improvement from the $29.9 mill -
Anika Narrows Q2 Loss, Revenue Up 7.7% on Strong Product Demand
— Jul 30, 2025 Risk: medium
Anika Therapeutics, Inc. reported a net loss of $1.5 million for the three months ended June 30, 2025, a significant improvement from the net loss of $10.2 mill -
Anika Therapeutics Q1 2025 10-Q Filed
— May 9, 2025 Risk: medium
Anika Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first qua -
Anika Therapeutics Files Q3 2024 10-Q
— Nov 4, 2024 Risk: medium
Anika Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business op -
Anika Therapeutics Q2 2024 10-Q Filed
— Aug 8, 2024 Risk: medium
Anika Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and first half of 202 -
Anika Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: low
Anika Therapeutics, Inc. (ANIK) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Anika Therapeutics, Inc. filed a 10-Q report for the period ending
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX